02-07-2025
Field Medical raises $35m to advance ablation system development
Field Medical has closed a $35m series B financing round for advancing the development of the FieldForce pulsed field ablation platform.
This round was co-led by BioStar Capital and Cue Growth, with contributions from current strategic investors.
The funds will also facilitate the launch of the pivotal VERITAS trial and strengthen the company's clinical and regulatory capabilities. It brings Field Medical's total funding to $75m.
BioStar Capital founder and senior managing director Dr Louis Cannon said: 'Field Medical's transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency.
'Their physician-led team brings the right insight, and their FieldForce platform brings the right tools.'
In 2024, the FieldForce ablation system received breakthrough device designation and was selected for the US Food and Drug Administration (FDA) TAP Pilot programme for ventricular tachycardia (VT).
The next-generation system has been designed for transmural lesion creation and provides a new approach to VT ablation.
It remains an investigational device, limited to research use under US law.
Field Medical founder and CEO Dr Steven Mickelsen said: 'VT is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need.
'We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.'
In conjunction with this growth funding, Field Medical has updated its board of directors.
The board includes Dr Steven Mickelsen, the company's founder and CEO; Mark Wisniewski, CFO of Enterra Medical; and Marlou Janssen, board member at Field Medical, Sonion, Acarix, EBAMed and Inspiration Healthcare.
Additional members comprise surgeon and entrepreneur Alexei Mlodinow and Cue Growth founding partner Ben Cannon.
"Field Medical raises $35m to advance ablation system development" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
